Reshma Kewalramani, CEO of Vertex Pharmaceuticals VRTX, has filed 2 purchases and 26 sales on the open market. Over the past 12 months that comes to a net sale of $19.7M. The latest trade was on 02/27.

RK

RK

Reshma Kewalramani

CEO & President

Company

Vertex Pharmaceuticals VRTX

First filing

23/01/27

Trades

66 trades

Buys / sales

2 / 26

12-month net buying

−$19.7M

Last trade

02/27

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	02/27	03/03	40,000 sh13 trades	$493.47avg.	$19,738,854.85	−28.9%
Vertex PharmaceuticalsVRTX	Open-market buy	25/08/06	25/08/07	10,000 sh2 trades	$389.58avg.	$3,895,767.7	+9.4%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/11/08	24/11/12	15,198 sh	$515.00	$7,826,970	−16.7%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/07/30	24/08/01	15,202 sh	$505.00	$7,677,010	−14.3%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/07/22	24/07/24	15,202 sh	$497.00	$7,555,394	−12.5%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/05/24	24/05/29	1,565 sh	$457.00	$715,205	−1.3%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/05/20	24/05/22	15,202 sh	$447.00	$6,795,294	−11.1%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/12/15	23/12/19	17,135 sh	$407.00	$6,973,945	−13.6%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/12/13	23/12/15	5,098 sh	$397.00	$2,023,906	−4.5%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/11/13	23/11/15	5,097 sh	$377.00	$1,921,569	−4.3%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/07/17	23/07/18	7,828 sh	$355.00	$2,778,940	−6.2%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/04/27	23/05/01	3,317 sh3 trades	$339.08avg.	$1,124,726.05	−2.6%
Vertex PharmaceuticalsVRTX	Open-market sale	23/01/25	23/01/27	10,000 sh	$315.05	$3,150,500	−10.0%